MEDS700

MEDS700 (0.001-10 μM; 3 days) induces differentiation and apoptosis in THP1 and U937 acute myeloid leukemia (AML) cell lines, with an EC₅₀ value ranging from 19 nM to 64 nM^[1].
MEDS700 (0.1-1 μM; 3 days) induces apoptosis in MV4-11 acute myeloid leukemia (AML) cells at concentrations of 0.1 μM and 1 μM^[1].
MEDS700 exhibits potent antiproliferative activity against a panel of solid tumor cell lines at nanomolar concentrations, with the strongest activity observed in neuroblastoma, Ewing sarcoma, bladder cancer and fibrosarcoma cells^[1].
MEDS700 potently inhibits the proliferation of SF7761 and SU-DIPG-XIII DMG cell lines, with EC₅₀ values of 9.3 nM and 32.9 nM, respectively, and exhibits activity in SF8628 cells with extended exposure time^[1].
MEDS700 (72 h) exerts antiproliferative and cytotoxic effects on SH-SY5Y neuroblastoma cells via pyrimidine depletion, induces S-phase cell cycle arrest, caspase-dependent apoptosis, and irreversible loss of colony-forming ability, with an EC₅₀ of 13 nM^[1].
MEDS700 (1-100 μM; 72 h) exhibits only extremely low toxicity in mixed neural cell cultures derived from human induced pluripotent stem cells (hiPSCs), with an EC₃₀ of 199 μM, indicating that this compound has a favorable safety window relative to its anti-tumor activity^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.